N-hexyl-2-methoxy-4-nitroaniline 在
钯 silica gel 作用下,
以
甲醇 为溶剂,
以yielding the raw product as violet solid matter (606 mg, ≈98%)的产率得到N1-hexyl-2-methoxybenzene-1,4-diamine
参考文献:
名称:
COMPOUNDS AS PPAR BETA/DELTA INHIBITORS FOR TREATING PPAR BETA/DELTA-MEDIATED DISEASES
ion involve attack of the amine upon a triplet excited state of NVT.Mechanistic evidences indicate that the reaction with hydroxide ion is probably a SN23Ar* process whereas the reaction with piperidine involves a radical ion pair formed via electron transfer from the amine to a triplet excited state. Photoreactions. with primary amines involve attack of the amine upon a singlet excited state of NVT
4-硝基veratrole(NVT)被伯胺,哌啶和氢氧根离子光取代。伯胺和氢氧根离子导致相对于硝基的位置上的甲氧基取代,而哌啶将硝基上的甲氧基取代。哌啶和氢氧根离子的光反应涉及胺对NVT三重激发态的攻击。机理证据表明,与氢氧根离子的反应可能是S N 2 3 Ar *过程,而与哌啶的反应则涉及通过电子从胺转移到三重激发态。光反应。伯胺的反应涉及胺对NVT(S的单重激发态)的攻击N 2 1 Ar *工艺)。在亲核试剂电离势的考虑因素和基态供体-受体复合物形成能力的背景下讨论并证明了这些结果。
On the regioselectivity of the nucleophilic aromatic photosubstitution. The photoreaction of 4-nitroveratrole with n-hexylamine.
[DE] VERBINDUNGEN ALS PPAR BETA/DELTA INHIBITOREN FÜR DIE BEHANDLUNG VON PPAR BETA/DELTA-VERMITTELTEN ERKRANKUNGEN<br/>[EN] COMPOUNDS AS PPAR BETA/DELTA INHIBITORS FOR TREATING PPAR BETA/DELTA-MEDIATED DISEASES<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DE PPAR BÊTA/DELTA POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR PPAR BÊTA/DELTA
申请人:UNIV MARBURG PHILIPPS
公开号:WO2012168345A1
公开(公告)日:2012-12-13
Die vorliegende Erfindung betrifft Substanzen, die als selektive Liganden von nukleären Rezeptoren des PPAR beta/delta-Subtyps wirken und für die Behandlung von PPAR beta/delta-vermittelten Erkrankungen verwendet werden können. Die erfindungsgemäßen Substanzen wirken als Inhibitoren des PPAR beta/delta Rezeptors.
COMPOUNDS AS PPAR BETA/DELTA INHIBITORS FOR TREATING PPAR BETA/DELTA-MEDIATED DISEASES
申请人:Diederich Wibke
公开号:US20150018411A1
公开(公告)日:2015-01-15
The present invention concerns substances which act as selective ligands of nuclear receptors of the PPAR beta/delta subtype and which can be used for the treatment of PPAR beta/delta-mediated diseases. The substances of this invention act as inhibitors of PPAR beta/delta receptors.